Disulfiram
Brand names: Antabuse
Disulfiram is an aversive agent used as an adjunct in the maintenance of abstinence in alcohol dependence.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde if alcohol is consumed, which produces an unpleasant flushing, headache, nausea and palpitation reaction that deters drinking.
Prescribing in practice
- A severe and potentially fatal reaction can occur with even small amounts of alcohol, including that in foods, medicines and toiletries, so patient understanding and supervision are essential.
- Contraindicated in cardiovascular disease, severe psychiatric illness and during pregnancy because of the risk of the alcohol-disulfiram reaction.
- Rare hepatotoxicity has been reported, so liver function should be checked and the drug stopped if hepatic dysfunction develops.
Monitoring
Monitor liver function and blood pressure during treatment and review adherence and abstinence regularly.
Counselling the patient
- Avoid all alcohol, including in foods, mouthwashes and over-the-counter medicines, throughout treatment and for a period after stopping.
- Seek urgent help if you experience chest pain, severe flushing or breathlessness.
- Treatment works best alongside psychological support and supervised administration.
Evidence & guidelines
Disulfiram is an established option for supervised relapse prevention, and NICE recommends it as an adjunct alongside psychosocial support in alcohol dependence.
Reference: NICE CG115 (Alcohol Dependence); NICE NG115; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Estimated Blood Alcohol Concentration · Toxicology
- Calculated Serum Osmolality · Electrolytes
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185